View Older Stories View More Recent Stories

Aug 27, 2020 09:30AM PAVmed to Present at The LD 500 Virtual Conference
Aug 18, 2020 04:14PM PAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update
Aug 6, 2020 09:27AM PAVmed Secures $7 Million Convertible Note Financing
Jul 28, 2020 09:30AM PAVmed to Hold Business Update Conference Call on August 18, 2020
Jul 13, 2020 09:30AM PAVmed to Present at Maxim Group’s COVID-19 Webinar on July 16, 2020
Jun 17, 2020 09:30AM PAVmed to Join the Russell 2000® and Russell 3000® Indexes
Jun 15, 2020 09:30AM Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor
Jun 11, 2020 09:31AM PAVmed (PAVM) Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard™ Esophageal DNA Test
Jun 11, 2020 09:30AM PAVmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard™ Esophageal DNA Test
Jun 3, 2020 09:30AM PAVmed Collaborates with Canon on DisappEAR™ Pediatric Ear Tubes
May 21, 2020 04:00PM PAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update
May 11, 2020 09:30AM PAVmed to Hold Business Update Conference Call on May 21, 2020
Apr 21, 2020 09:30AM PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device
Apr 9, 2020 04:50PM PAVmed (PAVM) Reports Prelim. Q4 EPS Below Consensus; Provides Business Update
Apr 9, 2020 04:44PM PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update
Apr 2, 2020 09:30AM PAVmed Subsidiary Lucid Diagnostics’ EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award
Mar 31, 2020 09:30AM PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing
Mar 24, 2020 09:30AM PAVmed to Hold Business Update Conference Call on April 9, 2020
Mar 9, 2020 09:30AM PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device
Mar 2, 2020 09:30AM PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
Feb 20, 2020 09:30AM PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™
Feb 18, 2020 09:30AM PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline
Feb 11, 2020 09:30AM U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test
Jan 13, 2020 09:31AM PAVmed (PAVM) Receives Formal Notification of Nasdaq Continued Listing Compliance
Jan 13, 2020 09:30AM PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
Dec 19, 2019 09:30AM PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test
Dec 13, 2019 09:30AM PAVmed Provides Update on CarpX™ Clinical Safety Study
Nov 21, 2019 04:00PM PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update
Nov 14, 2019 09:30AM PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products
Nov 7, 2019 09:30AM PAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple Milestones
Nov 6, 2019 09:30AM PAVmed to Hold Business Update Conference Call on November 21, 2019
Nov 5, 2019 07:00AM PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization
Sep 5, 2019 09:30AM PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update
Aug 21, 2019 09:30AM USPTO Grants PAVmed Patent Covering its CarpX™ Device
Aug 15, 2019 09:30AM PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submission
Aug 7, 2019 09:30AM PAVmed to Hold Business Update Conference Call on September 5, 2019
Jun 26, 2019 09:30AM PAVmed to Join Russell Microcap® Index
Jun 24, 2019 10:50AM PAVmed (PAVM) Subsidiary Receives FDA 510(k) Clearance for EsoCheck
Jun 24, 2019 10:46AM PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™
May 21, 2019 09:30AM PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update
May 20, 2019 09:30AM PAVmed Announces First Human CarpX™ Procedures
May 6, 2019 09:30AM PAVmed to Hold Business Update Conference Call on May 21, 2019
Apr 24, 2019 09:30AM PAVmed Reports Excellent DisappEAR™ Animal Study Results
Apr 12, 2019 09:35AM PAVmed (PAVM) Announces $1.6M Registered Direct Offering of its Common Stock
Apr 12, 2019 09:35AM PAVmed Announces Registered Direct Offering of its Common Stock
Apr 4, 2019 09:30AM PAVmed Reports Fourth Quarter 2018 Financial Results and Provides Business Update
Mar 21, 2019 07:30AM PAVmed to Hold Business Update Conference Call on April 4, 2019
Mar 20, 2019 07:30AM PAVmed Announces NextFlo™ Breakthrough
Mar 13, 2019 08:04AM PAVmed Announces PortIO™ Breakthrough
Feb 28, 2019 12:49PM PAVmed Subsidiary Lucid Diagnostics Launches World-Class Medical Advisory Board and Appoints Chief Medical Officer
View More Recent Stories View Older Stories